- Home
- VINE vs CDIO Comparison
VINE vs CDIO Comparison
Compare VINE & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINE
- CDIO
- Stock Information
- Founded
- VINE 2019
- CDIO 2017
- Country
- VINE United States
- CDIO United States
- Employees
- VINE N/A
- CDIO N/A
- Industry
- VINE Beverages (Production/Distribution)
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- VINE Consumer Staples
- CDIO Health Care
- Exchange
- VINE Nasdaq
- CDIO Nasdaq
- Market Cap
- VINE 11.0M
- CDIO 12.3M
- IPO Year
- VINE 2021
- CDIO N/A
- Fundamental
- Price
- VINE $0.69
- CDIO $0.53
- Analyst Decision
- VINE
- CDIO Buy
- Analyst Count
- VINE 0
- CDIO 1
- Target Price
- VINE N/A
- CDIO $2.00
- AVG Volume (30 Days)
- VINE 151.2K
- CDIO 2.5M
- Earning Date
- VINE 03-07-2025
- CDIO 11-13-2024
- Dividend Yield
- VINE N/A
- CDIO N/A
- EPS Growth
- VINE N/A
- CDIO N/A
- EPS
- VINE N/A
- CDIO N/A
- Revenue
- VINE $477,737.00
- CDIO $35,688.00
- Revenue This Year
- VINE N/A
- CDIO $2,081.66
- Revenue Next Year
- VINE N/A
- CDIO $43.84
- P/E Ratio
- VINE N/A
- CDIO N/A
- Revenue Growth
- VINE N/A
- CDIO 180.90
- 52 Week Low
- VINE $0.25
- CDIO $0.19
- 52 Week High
- VINE $1.25
- CDIO $2.40
- Technical
- Relative Strength Index (RSI)
- VINE 55.59
- CDIO 38.70
- Support Level
- VINE $0.51
- CDIO $0.49
- Resistance Level
- VINE $0.59
- CDIO $0.62
- Average True Range (ATR)
- VINE 0.08
- CDIO 0.11
- MACD
- VINE 0.00
- CDIO -0.06
- Stochastic Oscillator
- VINE 82.18
- CDIO 8.34
About VINE Fresh Vine Wine Inc.
Fresh Vine Wine Inc is a producer of low-carb, low-calorie premium wines in the United States. The company's wine collection features a California Cabernet Sauvignon, Pinot Noir, Chardonnay, California Rose wine, and a Limited Reserve Napa Cabernet.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.